U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06921837) titled 'A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer' on April 04.
Brief Summary: A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Gastric Cancer Adenocarcinoma Metastatic
Gastroesophageal Adenocarcinoma
Intervention:
DRUG: BDC-4182
Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Bolt Biotherapeutics, Inc.
Published by HT Dig...